The aim of this study is to reduce antibiotic prescriptions by use of a clinical decision rule in febrile children suspected for CAP with unchanged outcome. Specific research questions are: 1. Does a decision rule reduce the use of antibiotics in…
ID
Bron
Verkorte titel
Aandoening
children; pneumonia; prediction; antibiotic use; antibiotica; pneumonie; kinderen
Ondersteuning
Innovatiefonds zorgverzekeraars
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Number of (narrow-spectrum) antibiotic prescriptions and its percentage within the total included population (benefit); Strategy failures (children with complications of CAP within 7 days) (safety).
Achtergrond van het onderzoek
Unnecessary prescription of antibiotics highly contributes to the development of antibiotic resistance, a world wide threat to
health. We are in need to improve the recognition of children that benefit from antibiotic treatment for comunity-acquired
pneumonia (CAP).
Aim:
To safely reduce antibiotic prescription by a clinical decision rule (Feverkidstool) in febrile children suspected of CAP.
Design:
Stepped wedge trial with implementation of the Feverkidstool guiding antibiotic treatment in children suspected of CAP in 7
hospitals.
Population:
Febrile children (1 month – 5 years) at the emergency care department with signs of CAP in 7 Dutch hospitals.
Outcomes:
Primary: Number of antibiotic prescriptions (benefit); strategy failures within 7 days (safety). Secondary: Compliance to the rule;
Percentage of narrow spectrum antibiotics; Duration/doses of antibiotics; Complications of CAP; Costs of outcome measures.
Intervention:
Clinical decision rule (Feverkidstool) for the individual risk for CAP and other SBI guiding a targeted approach for antibiotic
prescription.
Analysis:
A generalized linear mixed model with antibiotic prescription as dependent will be used to correct for clustering in centers and
time-effects. Time-effects will be included as fixed effect. Covariates includes the predicted risk for CAP (low, intermediate and
high), patient age, triage urgency and season.
Power analysis:
A sample size of 1100 children with a suspicion of CAP in 24 months will be sensitive to detect an absolute reduction of 10%
(low risk) to 15% (intermediate risk) of antibiotic prescription with a power of 0.9 and an alpha of 0.05.
Schedule:
M0-3: preparation; M4-15 datacollection preimplementation; M13-15 implementation; M16-M27 datacollection
postimplementation; M28-30 Datanalysis, reporting.
Impact:
The Feverkidstool improves application of current insights on reduced antibiotic presicription in children suspected of CAP in
routine care.
Changes/Added information
dd 21-12-2016:
to provide sufficient inclusions we introduce an eighth hospital, Lange land hospital Zoetermeer
dd 20-8-2018
Interim analysis of inclusions during the first year showed a higher antibiotic prescription than previously assumed: in low risk children we observed 35-45% antibiotic prescription; in the intermediate group this is 40%. Therefore we assume a reduction of 15% in both the low and intermediate risk group. Remodelling with these numbers and similar assumptions as above shows that an effect of 15-20% antibiotic reduction can be assessed in a sample of 800-900 children.
Doel van het onderzoek
The aim of this study is to reduce antibiotic prescriptions by use of a clinical decision rule in febrile children suspected for CAP with unchanged outcome. Specific research questions are:
1. Does a decision rule reduce the use of antibiotics in children with suspected CAP?
2. Does the use of a decision rule do not harm those whose treatment is modified as a result?
3. What is the compliance to a decision rule guiding clinicians on treatment for childhood CAP?
4. What is the cost benefit of the implementation of the feverkidstool in the diagnostic evaluation of a child suspected of CAP?
Onderzoeksopzet
Month 1-3: Preparation study and preparation baseline data collection of eligible patients
Month 4-15: Preimplementation phase datacollection, development webbased dataregistry and feverkidstool. Evaluation possibilities to integrate the feverkidstool within the local ICT-environment
Month 13-15: Training ED personnel (nurses, paediatricians (in training)) in feverkidstool
Month 16-27: Postimplementation phase data collection of eligible patients (clinical characteristics, diagnoses and antibiotic therapy).
Month 28-30: Evaluation, datanalysis and interpretation; Writing report
Onderzoeksproduct en/of interventie
-Feverkidstool: a clinical decision rule that assess the individual risk for pneumonia in children with fever
-a risk based strategy for treatment advice (discharge, watchfull waiting, or antibiotics) will be applied
Publiek
R. Oostenbrink
Dr. Molewaterplein 60, Office Sp-1549
Rotterdam 3000 CB
The Netherlands
+ 31 (0)10 7036661
r.oostenbrink@erasmusmc.nl
Wetenschappelijk
R. Oostenbrink
Dr. Molewaterplein 60, Office Sp-1549
Rotterdam 3000 CB
The Netherlands
+ 31 (0)10 7036661
r.oostenbrink@erasmusmc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
children aged 1 month – 5 years with fever (parent reported and/or measured during physical examination T >38°C) with signs suspected of community acquired pneumonia (CAP)
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
-febrile children with antibiotic treatment during the week prior to the ED visit
-children with comorbidity, i.e. hemodynamic relevant cardiac disease, pulmonary, neurologic disease or (primary of secondary) immunodeficiency
-children with an obvious single other infectious focus (cutaneous, otitis media, rhinitis), those with signs of complicated pneumonia at the moment of presentation (i.e. respiratory failure, pleura empyema, pneumothorax, suspicion of septicaemia), those with (self-reported) intolerance of amoxicillin, and those with suspicion of resistant pathogens due to a visit to foreign countries 2 months prior to the ED visit
-patients not understanding or not able to act on safety-net instructions (due to language problems or logistics) in case of deterioration
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Toelichting
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL5178 |
NTR-old | NTR5326 |
Ander register | NL47593.078.14 : ZonMW 836041001 |